Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Mortality rates higher in hepatitis C virus carriers

Hepatitis C virus (HCV) is a blood-borne disease that causes inflammation of the liver and to which there is currently no vaccine available. The World Health Organization (WHO) estimates that 3% of the world's population, approximately 170 million people, are infected with HCV and it is a leading cause of liver cirrhosis, end stage liver disease, hepatocellular carcinoma (HCC) and liver transplantation.

31 Jul 2009

Hepatitis C infection: Treatment options equally effective, likelihood of success known early on

Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.

22 Jul 2009

Focusing HIV treatment helps control concurrent hepatitis B infection

Prolonged use of highly active antiretroviral therapy (HAART) to treat people infected with both HIV and hepatitis B (HBV) helps to better control the hepatitis B infection and could delay or prevent liver complications, according to a new study by researchers at Wake Forest University School of Medicine.

15 Jul 2009

Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy

An interdisciplinary team of researchers at Brigham and Women's Hospital and the Harvard-Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology has demonstrated a better way to deliver cancer drugs directly to tumors.

28 Jun 2009

Discovery of potent metastasis inhibitor

Researchers at Children's Hospital Boston have isolated a potent inhibitor of tumor metastasis made by tumor cells, one that could potentially be harnessed as a cancer treatment.

23 Jun 2009

Targeting tumor behavior may find new anti-cancer agents

Ohio State University cancer researchers have used computational and genomic methods to identify possible anti-cancer agents that may block a particular kind of tumor behavior. The agents target multiple genes associated with that behavior at one time.

18 Jun 2009

Improved toxicology test method

Researchers at Oregon State University recently completed the largest animal study ever done in the field of toxicology, and the findings challenge some basic concepts about how to determine what level of a cancer-causing compound can be considered safe.

18 Jun 2009

Trial of new ‘combo’ treatment for hepatitis C

In a multi-center trial led by a Saint Louis University researcher, investigators found that a new combination therapy of daily consensus interferon and ribavirin helps some hepatitis C patients who have not responded to previous treatment.

17 Jun 2009

Research leads to advanced trials of new cancer treatment

Prof. Hochberg was successful in isolating the H19 gene in humans and determining that it is significantly expressed in over 33 different forms of cancer, including superficial bladder carcinoma and pancreatic, ovarian and metastatic liver cancer, while laying dormant and non-expressed in non-cancerous cells.

15 Jun 2009

Study shows promise for new cancer-stopping therapy

Researchers at Nationwide Children's Hospital and Johns Hopkins University have discovered that delivering a small molecule that is highly expressed in normal tissues but lost in diseased cells can result in tumor suppression.

12 Jun 2009

Protein abundant in embryonic stem cells offers a new cancer target

A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.

1 Jun 2009

New device for coagulating and killing unwanted tissue during surgery

Acculis Limited, the UK based specialist microwave ablation company based in Denmead, England, has announced the clearance of its latest device for coagulating and killing unwanted tissue during surgery.

24 May 2009

Pioneering technique for treatment of liver tumours

Leicester consultant surgeon who has developed a pioneering technique using microwaves to destroy liver tumours has treated more than 100 patients in the UK and other patients are now being treated internationally.

12 May 2009

Study shows beneficial effects statins may have on gastrointestinal disorders

The commonly used prescription statin drugs may have a protective effect in the prevention of liver cancer and lead to a reduction in the need for gallbladder removals, according to two studies published in Gastroenterology.

5 May 2009

Women with a history of hypothyroidism at greater risk of developing liver cancer

Women with a history of hypothyroidism face a significantly higher risk of developing liver cancer, according to a new study in the May issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience.

4 May 2009

Anti-viral drug telaprevir improves response, halves duration of hepatitis C treatment

The addition of the anti-viral drug telaprevir to a standard treatment for hepatitis C can shorten the duration of therapy and increase the number of patients who can be cured of their disease, according to the results of study coordinated by investigators from the Duke Clinical Research Institute (DCRI).

29 Apr 2009